{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"Persistant Atrial Fibrillation: Pulse Field Ablation Dominates","description":"\u26a1\ud83e\udec0 Shock. Silence. Success \u2014 A landmark New England Journal of Medicine trial redefines first-line therapy in persistent AF. &amp;nbsp; In AVANT GUARD, pulsed field ablation (PFA) outperformed antiarrhythmic drugs: \ud83d\udcca Success: 56% vs 30% \ud83d\udcc9 HR: 0.46 (P&amp;lt;0.001) \ud83d\udc93 Lower arrhythmia burden (\u22126.5%) &amp;nbsp; Safety remained comparable, with primary events at 5.1%. &amp;nbsp; A compelling case for early, energy-based rhythm control\u2014precision over pharmacology. &amp;nbsp; #Cardiology #Electrophysiology #AtrialFibrillation #NEJM #Innovation ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41025810\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/201226765"}